These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 1854252

  • 1. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.
    Koretz MJ, Lawson DH, York RM, Graham SD, Murray DR, Gillespie TM, Levitt D, Sell KM.
    Arch Surg; 1991 Jul; 126(7):898-903. PubMed ID: 1854252
    [Abstract] [Full Text] [Related]

  • 2. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M, Clark JW, Smith JW, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG.
    J Natl Cancer Inst; 1992 Jun 17; 84(12):929-37. PubMed ID: 1629914
    [Abstract] [Full Text] [Related]

  • 3. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
    Gambacorti-Passerini C, Hank JA, Albertini MR, Borchert AA, Moore KH, Schiller JH, Bechhofer R, Borden EC, Storer B, Sondel PM.
    J Immunother Emphasis Tumor Immunol; 1993 Jan 17; 13(1):43-8. PubMed ID: 8435431
    [Abstract] [Full Text] [Related]

  • 4. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S.
    Cancer Res; 1990 Nov 15; 50(22):7343-50. PubMed ID: 2224862
    [Abstract] [Full Text] [Related]

  • 5. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH.
    J Clin Oncol; 1992 Feb 15; 10(2):275-81. PubMed ID: 1732429
    [Abstract] [Full Text] [Related]

  • 6. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
    Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA.
    Ann Intern Med; 1988 Apr 15; 108(4):518-23. PubMed ID: 3258138
    [Abstract] [Full Text] [Related]

  • 7. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar 15; 82(3):395-404. PubMed ID: 2072602
    [Abstract] [Full Text] [Related]

  • 8. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
    Nomura K, Fujioka T.
    Nihon Hinyokika Gakkai Zasshi; 1993 May 15; 84(5):831-40. PubMed ID: 8320888
    [Abstract] [Full Text] [Related]

  • 9. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
    Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF.
    Cancer; 1995 Sep 01; 76(5):824-32. PubMed ID: 8625186
    [Abstract] [Full Text] [Related]

  • 10. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
    Thompson JA, Bianco JA, Benyunes MC, Neubauer MA, Slattery JT, Fefer A.
    Cancer Res; 1994 Jul 01; 54(13):3436-41. PubMed ID: 8012963
    [Abstract] [Full Text] [Related]

  • 11. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
    Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH, Benz LA, Fefer A.
    J Clin Oncol; 1992 Jun 01; 10(6):960-8. PubMed ID: 1588376
    [Abstract] [Full Text] [Related]

  • 12. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E.
    Hinyokika Kiyo; 1992 Nov 01; 38(11):1305-9. PubMed ID: 1485586
    [Abstract] [Full Text] [Related]

  • 13. The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.
    Albertini MR, Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Bechhofer R, Storer B, Sondel PM.
    Cancer; 1990 Dec 15; 66(12):2457-64. PubMed ID: 2249185
    [Abstract] [Full Text] [Related]

  • 14. Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma.
    Vaglini M, Belli F, Santinami M, Arienti F, Parmiani G, Persiani L, Santoro N, Grazia Inglese M, D'Elia F, Cascinelli N.
    Ann Surg Oncol; 1995 Jan 15; 2(1):61-70. PubMed ID: 7834457
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K.
    Int J Urol; 1998 Jan 15; 5(1):16-21. PubMed ID: 9535595
    [Abstract] [Full Text] [Related]

  • 17. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
    Kuebler JP, Whitehead RP, Ward DL, Hemstreet GP, Bradley EC.
    J Urol; 1993 Sep 15; 150(3):814-20. PubMed ID: 8345590
    [Abstract] [Full Text] [Related]

  • 18. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
    Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA.
    J Natl Cancer Inst; 1993 Apr 21; 85(8):622-32. PubMed ID: 8468720
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.